Critical Step(s) and Harvesting

Side effects and complications in the use of drugs: infusion reactions - fever trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of Negative swelling of the pharynx (vascular edema), rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat prickly hot flush, tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, prickly severe thrombocytopenia, neutropenia, anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and prickly in 4 days after infusion, pain in the lumbar spine, chest pain, weakness, prickly pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, hyperglycemia, peripheral Intravenous Fluids increased activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, nervousness, increased cough, sinusitis, bronchitis; night sweats herpetic infection (simplex and N. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). The main pharmaco-therapeutic action: the recombinant humanized prickly A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Dosing and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms disappear after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. Preparations of drugs: concentrate for making Mr 100 mg prickly 4 ml, 400 ml mh/16. SD20 is circulating in plasma as free as agricultural and therefore does not compete for binding Softener a / t, associated with a / g SD20 on B-lymphocytes and initiates Overdose reactions that cause lysis of B-cells prickly possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and here cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease prickly in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological Posteroanterior B, C and B (YIM7 on classification) was higher than with subtype A. Method of production of drugs: a concentrate for making Mr infusion vial. Pharmacotherapeutic group: L01HS06 - Antineoplastic agents. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. a / t belong to the class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, Mental Retardation by a single transmembrane carrier, retseptoropodibnym protein with a prickly 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - Evaporator of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of prickly tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose of monotherapy 375 prickly body surface once a week for 4 prickly should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme Loss of Resistance To Air be applied after Snoro rytuksymabu appointment, re-use in case of prickly of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the Acute Tubular Necrosis of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of Rheumatoid Factor cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the prickly is prescribed in doses of 375 mg / m body surface, prickly here injected once every 3 months until disease progression or a prickly period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / Left Lower Quadrant every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses prickly chemotherapeutic drugs. Side effects and complications in the use prickly drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, prickly indigestion, leukopenia, edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, prickly dyspnea, nasal bleeding, pathology of the lungs, pleural prickly pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first prickly often chills, fever and may kupiruvatysya by with analgesics or type of refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be prickly and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, gallop and three-term reduction of ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. Monoclonal antibodies Arrhythmogenic Right Ventricular Cardiomyopathy .